Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Detection of signature double-negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function (2024) Eisenhauer N, Miano M, Naumann-Bartsch N, Leyh J, Dell'Orso G, Aigner M, Fecker G, et al. Journal article CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. (2024) Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, et al. Journal article Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. (2024) Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, et al. Journal article, Review article Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies (2024) Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, et al. Journal article, Letter Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. (2024) Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, et al. Journal article Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center. (2023) Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev E, et al. Journal article Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy (2023) Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, et al. Journal article Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains (2023) Reimann H, Moosmann C, Schober K, Lang V, Verhagen J, Zeun J, Mackensen A, et al. Journal article Inferior Outcomes of EU Versus US Patients Treated with CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use (2023) Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Journal article Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response (2023) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Journal article